Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × EGFR Mutated EGFR TKI Naive Metastatic NSCLC × Clear all
NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sierra Oncology LLC - a GSK company

Phase 1 Terminated
11 enrolled
Thoracic

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡